Drugs / ASP5541
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07339267 | Jan 2026 → Dec 2028 expected | prostate carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07005154 | Jun 2025 → May 2032 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP5541 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07339267 ↗ |
| Route | Intramuscular | “Intramuscular Injection” NCT07005154 ↗ |